EBE – the European Trade Association representing biopharmaceutical companies of all sizes.
About EBE
05 Dec 2017

Escher Study Identifies Hurdles to ATMP Development in Europe

First results of a study into factors associated with successful development of Advanced Therapy Medicinal Products (ATMPs) were reported today by Utrecht University at European Biopharmaceuti...

Read more
23 Nov 2017

EBE and EFPIA call for policy support to make personalised medicine a reality for patients

Ahead of the first congress of the European Alliance for Personalised Medicine (EAPM) “Personalising your health: A global imperative!” on 27-30 November 2017 in Belfast, the Joint EBE-EFPIA Perso...

Read more
10 Oct 2017

EBE and EFPIA call on the EU Commission and Member States to improve transparency on Hospital Exemptions for Advanced Therapies

“Therapies for the future - Exploring solutions for innovative treatments in Europe” will take place at the European Parliament  on 11 October 2017. In advance of this significant discussion...

Read more
14 Dec 2017

The associations representing the European and British life science industry have today launched a joint policy document on the potential impact of the United Kingdom’s exit the European Union

The associations representing the European and British life science industry (AESGP, ABPI, BIA, BGMA, EBE, EFPIA, EUCOPE, EuropaBio, Medicines for Europe, PAGB, Vaccines Europe) have today launche...

Read more
30 Nov 2017

EBE Concept Paper: Management and Control of Raw Materials Used in the Manufacture of Biological Medicinal Products

Effective management and control of raw materials (RM) used in the manufacture of biological medicinal products requires an appropriate framework to identify and focus on critical aspects that must be...

Read more
10 Oct 2017

EBE and EFPIA call on the EU Commission and Member States to improve transparency on Hospital Exemptions for Advanced Therapies

“Therapies for the future - Exploring solutions for innovative treatments in Europe” will take place at the European Parliament  on 11 October 2017. In advance of this significant discussion...

Read more
12 Dec 2017

Presentations from the 6th EBE Annual Conference on ATMPs – 5 December 2017, London

The remarkable opportunities that cell and gene therapies can offer, but also the seemingly increasing number of obstacles to their wide application, were presented to a full audience in London’...

Read more
07 Dec 2017

Incentives, IP and smaller companies: the story of Lysogene

How Lysogene contributes to improving health outcomes Founded in France in 2009, and employing 18 staff at the end of 2017, Lysogene specialises in gene therapy targeting rare, neurod...

Read more
01 Dec 2017

Incentives for Innovation: the story of Gilenya by Novartis

With over 7,000 medicines in development, new treatments will continue to change patients’ lives, slowing disease progression, avoiding illness and reducing overall costs for healthcar...

Read more

From Twitter

Assos for EU & British life science industry launch a joint policy doc on the potential impact of #Brexit https://t.co/RHkgDbTAIT @aesgp @ABPI_UK @Britishgenerics @EFPIA @EUCOPE @EuropaBio @medicinesforEU @PAGBselfcare @EBE_EU #Brexit4patients #eucouncil #LifeScienceCoalition

The associations representing the European and British life science industry @aesgp @ABPI_UK , @Britishgenerics @EFPIA @EUCOPE @EuropaBio @medicinesforEU , @PAGBselfcare @EBE_EU launch a joint policy doc on the potential impact of the UK's exit the EU
https://t.co/33u2sBRgjm

Broad EU-UK life science industry coalition calls for prioritizing medicines in Phase 2 #Brexit talks. Close regulatory coop, IP framework alignment, barriers-free trade must be at the top of the negotiating agenda 2 safeguard patient access to meds. https://t.co/rJi65KyrmN

Follow us